| Antibody
|
Company *
|
Target
|
Indication
|
Source
|
Approval *
|
| 3F8
|
Memorial Sloan-Kettering Merck
|
GD2
|
Detection and treatmenf of neuroblastoma
|
MOUSE; also with 124I or 131I
|
Clinical trials
|
| Abciximab (ReoPro®)
|
Centocor B.V. Eli Lilly& Co.
|
Platelet glycoprotein GPIIb/IIIa.
|
High risk angioplasty
|
CHIMERIC Fab fragment
|
FDA 1994
|
| Abagovomab
|
Menarini
|
Act as surrogate antigen
|
Ovarian cancer
|
MOUSE anti-idiotype
|
Clinical trials
|
| Adalimumab (Humira ® Trudexa®)
|
Abbott Laboratories
|
TNFα
|
Autoinmune disorders like arthritis reumatoid, psoriasis, Crohn's disease
|
HUMAN
|
FDA 2002 EMEA 2003
|
| Adecatumumab (MT201)
|
Micromet (MITI)
|
EpCAM-CD326
|
Tumor cells (prostate, breast cancers)
|
HUMAN
|
Clinical trials
|
| Afelimomab(Segard ™)
|
BASF, Abbot laboratories
|
TNFα
|
Sepsis
|
MOUSE (Fab')2 fragment
|
Failure of clinical trials
|
| Afutuzumab (Obinutuzumab) (GA-101, RO5072759)
|
Hoffmann-La Roche
|
CD20
|
Lymphoma
|
HUMANIZED
|
Clinical trials
|
| Alacizumab pegol (CDP791, gl65 DFM-PEG)
|
Celltech, UCB
|
VEGFR2
|
Non-small cell lung cancer
|
HUMANIZED F(ab')2 fragment- pegylated
|
Phase II Clinical trials
|
| ALD518 (BMS-945429)
|
Alder Biopharmaceuticals, Inc. / Bristol-Myers Squibb
|
IL-6
|
Rheumatoid arthritis
|
HUMANIZED aglycosylated
|
Phase II Clinical trials
|
| Alemtuzumab (Campath-1H®; MabCampath®)
|
Genzyme
|
CD52
|
Chronic lymphocytic leukaemia; T cell lymphoma
|
HUMANIZED
|
FDA 2001 EMEA 2001
|
| Altumomab pentetate (Hybri-CEAker™)
|
Hybritech incorporated
|
CEA
|
Diagnosis of colorectal cancer
|
MOUSE- pentetate-l11In
|
FDA orphan product 1990
|
| Anatumomab mafenatox (ABR-214936)
|
Active Biotech
|
Glycoprotein 5T4
|
Non-small cell lung cancer
|
MOUSE Fab fragment-superantigen staphylococcal enterotoxin E
|
Phase II Clinical trials
|
| Anrukinzumab (IMA-638)
|
Wyeth Pharmaceuticals
|
IL-13
|
Asthma, colitis ulcerosa
|
HUMANIZED
|
Clinical trials
|
| Apolizumab (HulDIO, REMITOGEN™ SMART™)
|
PDL (Protein Design Labs) BioPharma
|
HLA-DR β
|
Non-Hodgkin lymphoma, Chronic lymphocytic leukemia
|
HUMANIZED
|
Phase II Clinical trials
|
| Arcitumomab (CEA-Scan®)
|
Immunomedics Inc.
|
Carcinoembrionic antigen
|
Detection of tumors
|
MOUSE Ig Fragment- 99mTc
|
FDA 1996 EMEA1996 Retired 2005
|
| Aselizumab
|
?
|
CD62L
|
Immunosuppressive drug
|
HUMANIZED
|
Clinical trials
|
| Atlizumab (Tocilizumab) (Actemra®, RoActemra®)
|
Hoffman-la Roche Chugai Pharmaceuticals
|
IL-6 receptor
|
Rheumatoid arthritis
|
HUMANIZED
|
EMEA 2009 FDA 2010
|
| Atorolimumab
|
?
|
Rhesus factor
|
Immunosuppresive drug
|
HUMAN
|
?
|
| Bapineuzumab
|
Wyeth / Elan / Pfizer / J&J
|
β amyloid plaques
|
Alzheimer's disease/glaucoma
|
HUMANIZED
|
Clinical trials
|
| Basiliximab (Simulect ®)
|
Novartis Phamaceutical Corp.
|
CD25
|
Prevent rejection in organ transplantation
|
CHIMERIC
|
FDA 1998 EMEA 1998
|
| Bavituximab
|
Peregrine Pharmaceuticals, Inc
|
Phosphatidylserine
|
Cancer, viral infections
|
CHIMERIC
|
Clinical trials
|
| Bectumomab (LymphoScan®)
|
Immunomedics, Inc
|
CD22
|
Non-Hodgkin lymphoma
|
MOUSE Fab'fragment- 99mTc
|
?
|
| Belimumab (LymphoStat-B) (Benlysta®)
|
Human Genome Sciences GSK
|
BAFF (B cell activation factor)
|
systemic lupus erythematosus
|
HUMAN
|
FDA 2011
|
| Benralizumab (BIW-8405, MEDI-563)
|
Medlmmune Inc.
|
CD125 (IL-5 receptor)
|
Asthma
|
HUMANIZED
|
Phase II Clinical trials
|
| Bertilimumab (CAT-213)
|
Cambridge Antibody Technology; Ico Therapeutics
|
CC111 (Eotaxinl)
|
Severe allergic disorders
|
HUMAN
|
Clinical trials
|
| Besilesomab (Scintimun®)
|
Bayer Schering Pharma A. / CIS bio international
|
Carcinoembrionic antigen
|
Metastasis and inflammatory lesions
|
MOUSE- 99mTc
|
EMEA 2009
|
| Bevacizumab (Avastin®)
|
Genentech Inc./ Roche
|
VEGF-A
|
Cancer, age related macular degeneration
|
HUMANIZED
|
FDA 2004 EMEA 2005
|
| Biciromab(l11In) (FibriScint™)
|
Centocor
|
Fibrin II, β chain
|
Thromboembolism diagnosis
|
MOUSE Fab'fragment-111In
|
Withdrawn during clinical trials
|
| Bivatuzumab mertansine
|
Boehringer Ingelheim
|
CD44 v6
|
Squamous cell carcinoma
|
HUMANIZED-mertansine
|
Clinical trials
|
| Blinatumomab
|
Micromet Inc, Medlmmune
|
CD19/CD3
|
Non-Hodgkin lymphoma, acute lymphoblastic leukemia
|
MOUSE
|
Orphan drug (EME A/FDA)
|
| Brentuximab vedotin (SGN-35 and previously cAOO-vcMMAE)
|
Seattle Genetics and Millennium
|
CD30
|
Anaplastic large cell lymphoma; Hodgkin lymphoma
|
CHIMERIC (mouse/human)-auristatine
|
Clinical trials
|
| Briakinumab (ABT-874)
|
Cambridge Antibody Technology; Abbott Laboratories
|
IL-12andIL-23
|
Psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.
|
HUMAN
|
Clinical trials Ozespa, withdrawn for EMA
|
| Canakinumab (Ilaris®)
|
Novartis Phamaceutical Corp.
|
IL-1β
|
Ceryopyrin-associated periodic syndromes
|
HUMAN
|
FDA 2009 EMEA 2009
|
| Cantuzumab mertansine (huC242-DMl, SB408075)
|
GlaxoSmithKline / ImmunoGen Inc.
|
Mucin CanAg
|
Colorectal tumor, Pancreatic cancers
|
HUMANIZED-mertansine
|
Phase I/II Clinical trials
|
| Capromab Pendetide (111In) (ProstaScint®)
|
Cytogen Corp.
|
Prostate antigen
|
Detection of prostate tumor.
|
MOUSE-pentetide-111In
|
FDA 1996
|
| Catumaxomab (Removab®)
|
TRION Pharma
|
EpCAM and T cells-
|
Malignant ascitis with EpCAM-positive carcinomas
|
trifuncional antibody
|
EMEA 2009
|
| 125I-CC49
|
?
|
TAG-72
|
Detection of tumors
|
MOUSE-125I
|
no tumour response, in Phase I and II trials
|
| Cedelizumab (ORTHOCLONE OKT4 A)
|
Centocor Ortho Biotech Products LP
|
CD4
|
Prevention of organ transplant rejections and the treatment of autoimmune diseases
|
HUMANIZED
|
Phase II Clinical trials
|
| Certolizumab pegol (Cimzia®)
|
UCB
|
TNFα
|
Morbus Crohn, rheumatoid arthritis
|
HUMANIZED Fab-pegylated
|
FDA 2008
|
| Cetuximab, C-225 (Erbitux®)
|
Imclone Systems/ Bristol-Myers Squibb/ Merck KgaA
|
EGFR
|
Colorectal, Head and neck cancer
|
CHIMERIC
|
FDA 2004 EMEA 2004
|
| ch-TNT
|
Shanghai Medipharm Biotech
|
DNA associated antigens
|
Advanced lung cancer
|
CHIMERIC-131I
|
China 2003
|
| Citatuzumab bogatox VB6-845
|
|
TACSTD1
|
Ovarian cancer, solid tumors
|
HUMANIZED Fab fragment-bouganin
|
Pre-clinical trials
|
| Cixutumumab
|
Imclone Systems
|
IGF-1 receptor
|
Solid tumors
|
HUMAN
|
Clinical trials
|
| Clenoliximab
|
|
CD4
|
Rheumatoid arthritis
|
CHIMERIC (primate/human)
|
|
| Clivatuzumab tetraxetan yttrium (90 Y)
|
Immunomedics Inc.
|
MUC1
|
Pancreatic cancer
|
HUMANIZED
|
Phase II Clinical trials
|
| Conatumumab (AMG-655)
|
Amgen
|
TNFRSF10B, TRAIL-R2 (CD262)
|
Solid tumors
|
HUMAN
|
Clinical trials
|
| CR6261
|
The Scripps Research Institute, Crucell
|
Influenza A hemagglutinin
|
Influenza virus infection
|
HUMAN
|
Preclinical trials
|
| Dacetuzumab (SGN 40 or huS2C6)
|
Seattle Genetics
|
CD40
|
Non- Hodgkin's lymphoma and hematological malignancies
|
HUMANIZED
|
Clinical trials
|
| Daclizumab (Zenapax®)
|
Hoffman-La Roche
|
CD25 (IL-2 receptor)
|
Refractory unstable angina. Allograft rejection
|
HUMANIZED
|
FDA 1997 EMEA 1999
|
| Daratumumab
|
Genmab
|
CD38
|
Multiple myeloma
|
HUMAN
|
Clinical trials
|
| Denosumab XGEVA (Prolia®)
|
XGEVA, Amgen
|
RANKL
|
Postmenopausal osteoporosis
|
HUMAN
|
FDA 2010 EMEA 2010
|
| Detumomab
|
?
|
B cell lymphoma
|
B cell lymphoma
|
MOUSE
|
?
|
| Ecromeximab (KW2871)
|
Kyowa Hakko Kogyo Co., Ludwig Institute for Cancer Research
|
GD3 ganglioside
|
melanoma
|
CHIMERIC (mouse/human)
|
Phase I/II Clinical trials
|
| Eculizumab (Soliris®)
|
Alexion Pharmaceuticals
|
C5 Complement factor
|
paroxysmal nocturnal hemoglobinuria
|
HUMANIZED
|
FDA 2007 EMEA 2007
|
| Edobacomab (E5, XMMEN-0E5)
|
Pfizer
|
Endotoxin
|
Sepsis
|
MOUSE
|
Clinical trials
|
| Edrecolomab (Panorex®)
|
Imaging Sciences L1c
|
EpCAM (17-1A)
|
Colorectal cancers
|
CHIMERIC
|
German approval 1995
|
| Efalizumab (Raptiva®)
|
Genentech Inc./ Roche
|
CDlla
|
Psoriais
|
HUMANIZED
|
FDA 2003. Recommended suspension. Withdrawn from market 2009
|
| Efungumab (Mycograb®)
|
NeuTec Pharma (Novartis)
|
Fungal HSP90
|
Candida infection
|
HUMAN single chain variable fragment (scFv)
|
Discontinued the development on 2010
|
| Elotuzumab (HuLuc63)
|
PDL BioPharma Bristol Myers
|
SLAMf7(CD319)
|
Multiple myeloma
|
HUMANIZED
|
Clinical trials
|
| Elsilimomab (B-E8)
|
?
|
IL-6
|
Lymphoma/Myeloma
|
MOUSE
|
preliminary Clinical trials
|
| Enlimomab pegol
|
Boehringer Ingelheim Pharmaceuticals
|
ICAM-1 (CD54)
|
Immunomodulator, renal transplant rejection
|
MOUSE
|
Clinical trials
|
| Epitumomab cituxetan 90Y
|
?
|
Episialin
|
Several type of cancers. Epithelial Ovarian cancers
|
MOUSE- 90Y
|
Phase II
|
| Epratuzumab
|
UCB and Immunomedics
|
CD22
|
Autoinmune disorders such as lupus, Cancer
|
HUMANIZED
|
Clinical trials
|
| Erlizumab (rhuMAbCD18)
|
Genentech/Roche
|
CD18
|
Heart attack, stroke, traumatic shock
|
HUMANIZED F(ab')2fragment
|
Dropped
|
| Ertumaxomab (Rexomun®)
|
Fresenius Biotech GmbH / TRION Pharma
|
HER2/neu, CD3
|
Breast cancer
|
RAT/MOUSE HYBRID trifucntional antibody
|
Phase II Clinical trials
|
| Etaracizumab o Etaratuzumab MEDI-522 (Abegrin® or Vitaxin)
|
Medlmmime, Inc.
|
Integrin αv β3
|
Several type of cancers
|
HUMANIZED
|
Clinical trials
|
| Exbivirumab
|
?
|
Hepatitis B surface antigen
|
Hepatitis B infections
|
HUMAN
|
Preclinical
|
| Fanolesomab (NeutroSpec™)
|
Palatin Technologies
|
CD15
|
Apendicitis
|
MOUSE IgM-99mTc-
|
FDA 2004 Suspended in 2005
|
| Faralimomab
|
?
|
Interferon receptor
|
Immunomodulator
|
MOUSE
|
?
|
| Farletuzumab (MORAb-003)
|
Morphotek
|
FR-α
|
Ovarian cancer
|
HUMANIZED
|
Phase III Clinical trials
|
| Felvizumab (SB 209763)
|
Centocor Inc. / GlaxoSmithKline
|
Respiratory syncytial virus
|
Infection by RSV
|
HUMANIZED
|
Phase III Clinical trials
|
| Fezakinumab (ILV-094)
|
Wyeth - Pfizer
|
IL-22
|
Rheumatoid arthritis, psoriasis
|
HUMAN
|
Phase II Clinical trials
|
| Figitumumab (CP-751871)
|
Pfizer
|
IGF-1 receptor
|
Various types of cancers
|
HUMAN
|
Clinical trials
|
| Fontolizumab (HuZAF-™)
|
Novartis Pharmaceuticals Corp. / PDL (Protein Design Labs) BioPharma
|
Interferon γ
|
Auto-immune diseases like Crohn's disease
|
HUMANIZED
|
Rheumatoid Arthritis dropped, Phase II Clinical trials
|
| Foravirumab (CR4098)
|
Crucell
|
Rabies virus glycoprotein
|
Infection by rabies virus
|
HUMAN
|
Phase II Clinical trials
|
| Fresolimumab
|
Genzyme
|
TGF β
|
Pulmonar fibrosis/cancer
|
HUMAN
|
Clinical trials 2009
|
| Galiximab (IDEC-114)
|
Biogen Idee
|
CD80
|
B cell lymphoma, Non-Hodgkin's lymphoma, Psoriasis
|
CHIMERIC (primate/human)
|
Phase I/II Clinical trials
|
| Gantenerumab (R1450)
|
F. Hoffmann-La Roche Ltd.
|
β amyloid
|
Alzheimer's disease
|
HUMAN
|
Phase I Clinical trials
|
| Gavilimomab (ABX-CBL)
|
Abgenix
|
CD 147
|
Graft versus host disease
|
MOUSE
|
Phase II/III Clinical trials
|
| Gemtuzumab ozogamicin (Mylotarg®,CMA-676)
|
Wyeth → Pfizer
|
CD33
|
Relapsed acute myeloid leukaemia
|
HUMANIZED-Calicheamicin
|
FDA 2000 Suspended in US on 2010
|
| Girentuximab (Rencarex®cG250, WX-G250)
|
Wilex AG, Ludwig Institute for Cancer Research
|
Carbonic anhydrase 9 (CA-LX, MN, G250)
|
Renal carcinoma
|
CHIMERIC
|
Phase III Clinical trials
|
| Girentuximab (Redectane®, 124I_cG250, 1241 WX-G250)
|
Wilex AG, Ludwig Institute for Cancer Research
|
Carbonic anhydrase 9 (CA-IX, MN, G250)
|
Renal mass, kidney tumors
|
CHIMERIC
|
Phase III Clinical trials
|
| Glembatumumab vedotin(CR011,CDX-011)
|
Celldex Therapeutics, Inc.
|
GPNMB (transmembrane glycoprotein NMB)
|
Cancer cells expresing NMB: melanoma, breast cancer
|
HUMAN- Auristatin
|
Phase II Clinical trials
|
| Golimumab (Simponi®)
|
J&J
|
TNFα
|
Rheumatoid arthritis, psoriatic arthritis and ankylosing spondulitis
|
HUMAN
|
FDA 2009 EMEA 2009
|
| Gomiliximab
|
IDEC Pharmaceuticals Corporation
|
CD23
|
Allergic asthma
|
CHIMERIC (primate/human)
|
withdrawn
|
| Ibalizumab (TMB-355)
|
Tanox; TaiMed Biologies
|
CD4
|
HIV entry inhibitor
|
HUMANIZED
|
Clinical trials
|
| Ibritumomab tiuxetan (Zevalin®)
|
Biogen IDEC Pharmaceuticals Corp.
|
CD20
|
Non-Hodgkin lymphoma
|
MOUSE Ig- 90Y
|
FDA 2002 EMEA 2004
|
| Igovomab (Indimacis-125®)
|
CIS Bio international
|
MUC16CA-125
|
Ovarian cancer
|
MOUSE conjugated to 111In
|
FDA 1996, EC withdrawal 1999
|
| Imciromab-Pentetate (Myoscint™)
|
Centocor
|
Heart myosin
|
Detection of heart disease
|
MOUSE conjugated to 111In
|
FDA Orphan product 1989; Withdrawn in 1993
|
| Infliximab (Remicade®)
|
Centocor (J&J)
|
TNFα
|
Psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis.
|
CHIMERIC (mouse/human)
|
FDA 1998 /EMEA 1999
|
| Inolimomab
|
OPI (Orphan Pharma International)
|
IL2RA, CD25
|
Graft-veraMi-host disease
|
MOUSE
|
Phase II/III Clinical trials
|
| Inotuzumab ozogamicin (CMC-544)
|
Wyeth - Pfizer
|
CD22
|
Diffuse large B cell lymphoma, Non-Hodgkin lymphoma
|
HUMANIZED -Calicheamicin
|
Phase II Clinical trials
|
| Ipilimumab (MDX-101) (Yervoy™)
|
Bristol-Myers Squibb.
|
CD 152 (CTLA-4)
|
Activator of the immune system: late stage melanoma and other type of tumors
|
HUMAN
|
FDA 2011
|
| Iratumumab (MDX-060)
|
Medarex, Inc.- Bristol-Myers Squibb
|
CD30
|
CD30-positive lymphoma including Hodgkin's disease
|
HUMAN
|
Phase II Clinical trials
|
| Keliximab(IDECCE9.1/SB-210396)
|
Biogen IDEC Pharmaceuticals, SKB
|
CD4
|
Immunosuppressor. Severe chronicAsthma, Rheumatoid arthritis
|
CHIMERIC (primate/human)
|
Phase III Clinical trials suspended
|
| Labetuzumab (hMN14, CEACIDE™)
|
Immunomedics, Inc
|
CEA
|
Colorectal tumor
|
HUMANIZED
|
Phase I/II Clinical trials
|
| Lebrikizumab (MILR1444A)
|
Roche-Genentech
|
IL-13
|
Asthma
|
HUMANIZED
|
Phase II Clinical trials
|
| Lemalesomab
|
?
|
NCA-90 (granulocyte antigen)
|
Diagnosis of inflammatory lesions
|
MOUSE
|
?
|
| Lerdelimumab (CAT-152)
|
Cambridge Antibody Technology
|
TGF β
|
Immunosuppresor. Glaucoma
|
HUMAN
|
Phase III Clinical trials
|
| Lexatumumab (ETR2-ST01)
|
HGS; Cambridge Antibody Technology
|
TRAIL-R2 (AP02)
|
Tumors
|
HUMAN
|
Clinical trials
|
| Libivirumab
|
?
|
Hepatitis B surface antigen
|
Hepatitis B infection
|
HUMAN
|
Preclinical
|
| Lintuzumab
|
Seattle Genetics
|
CD33
|
acute myeloid leukemia
|
HUMANIZED
|
Clinical trials
|
| Lorvotuzumab mertansine IMGN901
|
ImmunoGen, Inc
|
CD56
|
Small cell lung cancer, ovarian cancer
|
HUMANIZED -mertansine
|
Orphan drug; clinical trials
|
| Lucatumumab
|
Novartis Pharmaceuticals Corp
|
CD40
|
Cancer like multiple myeloma, non-Hodgkin's or Hodgkin's lymphoma
|
HUMAN
|
Clinical trials
|
| Lumiliximab(IDEC-152,P5E8)
|
Biogen IDEC Pharmaceutical
|
CD23
|
Chronic lymphocytic leukaemia, Allergic asthma
|
CHIMERIC (primate/human)
|
Phase I/II Clinical trials
|
| Mapatumumab
|
Cambridge Antibody Technology and Human Genome Sciences, Inc.
|
TRAIL-receptor (death receptor 4
|
Several tumors
|
HUMAN
|
Clinical trials
|
| Maslimomab
|
?
|
T cell receptor
|
Immunosuppresor
|
MOUSE
|
?
|
| Matuzumab (EMD 72000)
|
Merck Serono; Takeda Pharmaceutical,
|
EGFR
|
Several tumors
|
HUMANIZED
|
Dropped
|
| Mepolizumab
|
GlaxoSmithKline
|
IL-5
|
Hypereosinophilic syndrome
|
HUMANIZED
|
Clinical trials
|
| Metelimumab (CAT-192)
|
Cambridge Antibody Technology
|
TGF β1
|
Scleroderma
|
HUMAN
|
Dropped
|
| Milatuzumab
|
Immimomedics, Inc
|
CD74
|
Multiple myeloma
|
HUMANIZED-doxorubicin
|
Clinical trials
|
| Minretumomab
|
?
|
TAG-72
|
Cancer
|
MOUSE
|
?
|
| Mitumomab (BEC2)
|
ImClone Systems Inc./ Memorial Sloan-Kettering Cancer Center/Merck KgaA
|
GD3 ganglioside
|
Melanoma and Small cell lung carcinoma
|
MOUSE
|
Phase III Clinical trials
|
| Morolimumab
|
?
|
Rhesus factor
|
Immunosuppresor
|
HUMAN
|
?
|
| Motavizumab (Numax)
|
Medlmmune
|
RSV glycoprotein F
|
Prevention of respiratory syncitial inf.
|
HUMANIZED
|
FDA withdrawn 2010
|
| Muromonab-CD3. (Orthoclone OKT3™)
|
Ortho Biotech, Inc. (subsidiary of J&J) Janssen-Cilag
|
CD3
|
Prevention of organ transplant rejection
|
MOUSE
|
FDA 1986 EMEA 1987
|
| Nacolomab tafenatox
|
?
|
C242
|
Colorectal tumor
|
MOUSE-enterotoxin A from Staphylococcus aureus
|
?
|
| Naptumomab estafenatox (ABR-217620, ANYARA, TTS CD3)
|
Active Biotech AB
|
TPBG (trophoblast glycoprotein, 5T4)
|
Several tumors
|
MOUSE Fab fragment-enterotoxin E from Staphylococcus aureus
|
Clinical trials
|
| Natalizumab (Tysabri®)
|
Biogen Idee and Elan Corp.
|
Integrin α4 subunit ofa4β1
|
Multiple Sclerosis, Chron's disease
|
HUMANIZED
|
FDA 2004/ withdrawn/ back on2006/ EMEA only for restricted cases
|
| Nebacumab (centoxin, HA-1A. septomonab)
|
Centocor
|
Endotoxin
|
Sepsis
|
HUMAN
|
Withdrawn in 1993
|
| Necitumumab (IMC-11F8)
|
ImClone Systems Inc.
|
EGFR
|
Several tumors
|
HUMAN
|
Clinical trials
|
| Nerelimomab
|
?
|
TNFα
|
TNF inhibitor
|
MOUSE
|
?
|
| Nimotuzumab (BIOMab EGFR®) (TheraCIM) (TheraLoc) (CIMAher)
|
CIM, Cuba YM Biosciences, Out-licensed to other companies Daiichi Sankyo, Inc (ONLY JAPAN)
|
EGFR
|
Squamous cell carcinoma and glioma
|
HUMANIZED
|
Orphan drug FDA, EMEA 2004, Several countries 2005 China; 2006 India.
|
| Nofetumomab merpentan (Verluma®)
|
Boehringer Ingelheim Pharma KG
|
Glycoprotein 40 kD
|
Detection of tumors
|
MOUSE Fab IgG2b-merpentan-99mTc
|
FDA 1996
|
| Ocrelizumab
|
Hoffman-La Roche Inc.
|
CD20
|
Immunosuppresive drug
|
HUMANIZED
|
Clinical trials
|
| Odulimomab. (afolimomab. ANTILFA®)
|
Pasteur-Merieux
|
integrin α L subunit -CDlla
|
Allograft Transplant rejection
|
MOUSE
|
Phase III, not renewed
|
| Ofatumumab (Arzerra HuMax-CD20®)
|
Genmab
|
CD20
|
Chronic lymphocytic leukemia
|
HUMAN
|
FDA 2009 EMEA 2010
|
| Olaratumab (IMC-3G3)
|
Imclone
|
PDGF-Rα
|
Solid tumors
|
HUMAN
|
Phase I Clinical trials
|
| Omalizumab (Xolair®)
|
Genentech Inc./ Roche/ Tanox, Inc., Novartis Pharmaceuticals
|
IgE
|
Severe asthma.
|
HUMANIZED
|
FDA 2003 EMEA 2005
|
| Oportuzumab monatox. (PROXINIUM™ VICINIUM™)
|
Viventia Biotechnologies Inc.
|
EpCAM, and others
|
Several tumors
|
HUMANIZED (sc Fv)- Pseudomonas aeruginosa exotoxin A
|
Phase II/III Clinical trials
|
| Oregovomab (OVAREX®)
|
AltaRex Corp
|
MUC16, CA-125
|
Ovarian tumors
|
MOUSE
|
Phase II Clinical trials
|
| Otelixizumab TRX4
|
Tolerx, Inc. AND GlaxoSmithKline. Manufact. by Abbott Laboratories
|
CD3ε
|
Type 1 diabetes and other autoimmune diseases
|
CHIMERIC/HUMANIZED
|
Clinical trials. Orfan drug status FDA
|
| Pagibaximab
|
Biosynexus, Glaxo Smith Kline
|
Staphylococcal lipoteichoic acid
|
Prevention of sepsis by staphylococcus
|
CHIMERIC (mouse/human)
|
Orphan drug status EMEA 2010
|
| Palivizumab (Synagis™)
|
Medimmune Inc.
|
An epitope of the RSV F protein
|
Respiratory syncitial virus infection
|
HUMANIZED
|
FDA 1998 EMEA 1999
|
| Panitumumab (ABX-EGF) (Vectibix™)
|
Amgen/Abgenix
|
Epidermal growth factor receptor (EGFR)
|
Metastatic colorectal carcinoma
|
HUMAN
|
FDA 2006 EMEA 2007
|
| Panobacumab (o Aerumab 11) (KBPA-101)
|
Kenta Biotech Ltd
|
Pseudomona aeruginosa serotype ATS 01l
|
Infection by pseudomona
|
HUMAN
|
Phase I/II Clinical trials
|
| Pascolizumab
|
Centocor Inc. / GlaxoSmithKline
|
IL-4
|
Allergy, Asthma
|
HUMANIZED
|
Phase II Clinical trials
|
| Pemtumomab (Theragyn)
|
Antisoma pic Abbot Laboratories
|
MUC1
|
Ovarian and peritoneal cancer
|
MOUSE
|
Clinical trials; orphan drug status in FDA and EMEA
|
| Pertuzumab (Omnitarg™)
|
Genentech
|
HER2
|
Tumors
|
HUMANIZED
|
Clinical trials
|
| Pexelizumab
|
Procter & Gamble (P&G) Alexion Pharmaceuticals
|
C5 Complement component
|
Reduce side effects of coronary artery bypass grafting and angioplasty
|
HUMANIZED
|
Disappointing results on phase III.
|
| Pintumomab technetium -99mTc
|
?
|
Adenocarcinoma antigen
|
Imaging of adenocarcinoma
|
MOUSE-99mTc
|
?
|
| Priliximab
|
Centocor
|
CD4
|
Crohn's disease and multiple sclerosis
|
CHIMERIC (mouse/human)
|
pending
|
| Pritumumab
|
Nascent Biologies, Inc.
|
Vimentin
|
Brain cancer
|
HUMAN
|
Clinical trials
|
| Pro 140
|
Progenies Pharmaceuticals
|
CCR5
|
HIV infection
|
HUMANIZED
|
Clinical trials/ fast track approval
|
| Rafivirumab (CR57)
|
Crucell
|
Rabies virus glycoprotein
|
Rabies profilaxis
|
HUMAN
|
Phase II Clinical trials
|
| Ramucirumab (IMC-1121B)
|
Pfizer/ImClone Systems Inc
|
VEGFR-2
|
Several tumors
|
HUMAN
|
Clinical trials.
|
| Ranibizumab (Lucentis®)
|
Genentech Inc. (Roche) / Novartis
|
Vascular endothelial growth factor A (VEGF-A)
|
Wet Macular degeneration
|
HUMANIZED Fab
|
FDA 2006 EMEA 2007
|
| Raxibacumab (ABthrax)
|
Human Genome Sciences
|
Protective antigen of anthrax toxin
|
Antrax toxin
|
HUMAN
|
Phase III Clinical trials
|
| Regavirumab
|
Teijin
|
Cytomegalovirus glycoprotein B
|
Cytomegalovirus infection
|
HUMAN
|
Phase I Clinical trials
|
| Reslizumab
|
Ception Therapeutics, Inc
|
IL-5
|
Eosinophil-meditated inflammations
|
HUMANIZED (from rat)
|
Phase II Clinical trials
|
| Rituximab (Rituxan®) (MabThera®)
|
Roche / Biogen Idee
|
CD20
|
Non-Hodgkin lymphomas, rheumatoid arthritis
|
CHIMERIC
|
FDA 1997 EMEA 1998
|
| Robatumumab (SCH 717454)
|
Schering-Plough.
|
CD221
|
Colon sarcoma, Blood cancers
|
HUMAN
|
Preclinical and Phase II Clinical trials
|
| Rontalizumab
|
Genentech Inc.
|
IFNα
|
Systemic lupus erythematosus
|
HUMANIZED
|
Clinical trials.
|
| Rovelizumab (LeukArrest, Hu23FG2)
|
Icos
|
CD11,CD18
|
Immunosuppresive drug
|
HUMANIZED
|
FDA 1998, dropped 2000
|
| Ruplizumab (Antova™)
|
Biogen Idee Ma Inc.
|
CD154
|
Rheumatic diseases
|
HUMANIZED
|
FSA fast tracked
|
| Satumomab pendetide (OncoScint CR103™)
|
Cytogen Corp. and Cetus Corp, Lonza Biologies
|
TAG-72
|
Ovarian and Colorectal Cancer diagnosis
|
MOUSE-pentetide- 11lIn
|
Withdrawn
|
| Sevirumab (MSL-109) (Protovir™)
|
Novartis Pharmaceuticals Corp. / PDL (Protein Design Labs) BioPharma
|
CMV
|
Cytomegalovirus infection in AIDS patients
|
HUMAN
|
Phase III
|
| Sibrotuzumab
|
?
|
FAP
|
Tumors
|
HUMANIZED
|
|
| Siltuximab
|
Centocor Inc.
|
IL-6
|
Multiple myeloma and other Tumors
|
CHIMERIC (mouse/human)
|
Phase II Clinical trials
|
| Siplizumab (MEDI-507)
|
BioTransplant, Medlmmune Inc.
|
CD2
|
Psoriasis and in the prevention of graft-verms - host disease, and Acute kidney transplant rejection
|
HUMANIZED (from rat)
|
Phase II Clinical trials
|
| Solanezumab
|
Eli Lilly
|
βamyloid
|
Alzheimer's disease
|
HUMANIZED
|
Phase II Clinical trials
|
| Stamulumab (MYO-029)
|
Cambridge Antibody Technology, Wyeth Pharmaceuticals
|
Myostatin
|
Muscular distrophy
|
HUMAN
|
Phase I/II Clinical trials
|
| Sulesomab-Technetium (Leukoscan®)
|
Immunomedics Inc, Nycomed GmbH
|
NCA-90 (granulocyte cell antigen
|
Detection of inflammation, diagnosing osteomyelitis
|
MOUSE- 99mTc
|
marketed in European Union
|
| Tacatuzumab tetraxetan-yttrium (90Y) (AFP-Cide)
|
Immunomedics Inc.
|
α fetoprotein (AFP)
|
Cancers
|
HUMANIZED-tetraxetan-90y
|
withdrawn
|
| Tadocizumab (C4Gl,YM-337)
|
Yamanochi Pharma America, PDL (Protein Design Labs) BioPharma
|
Integrin αIIbβ3
|
Percutaneous coronary interventions
|
HUMANIZED Fab
|
Phase II Clinical trials
|
| Talizumab (TNX-901)
|
Tanox, Novartis
|
Fc region of IgE
|
Allergy reactions
|
HUMANIZED
|
withdrawn
|
| Tanezumab (RN624)
|
Pfizer
|
Nerve growth factor (NGF)
|
Pain treatment
|
HUMANIZED
|
Clinical trials
|
| Taplitumomab paptox
|
?
|
CD19
|
Tumors
|
MOUSE- conjugated with antiviral protein PAP from Phytolacca americana
|
?
|
| Tefibazumab (Aurexis®)
|
Inhibitex
|
Clumping factor A
|
Severe infectious with Staphylococcus a.
|
HUMANIZED
|
Clinical trials
|
| Telimomab aritox
|
?
|
|
Immunosuppresive drug
|
MOUSE (Fab fragment)-ricin protein
|
1991, phase I, discontinued
|
| Tenatumomab
|
Sigma-Tau
|
Tenascin C
|
Cancer
|
MOUSE
|
?
|
| Teneliximab
|
?
|
CD40
|
Immunosuppresive drug
|
CHIMERIC (mouse/human)
|
?
|
| Teplizumab MGA031
|
Eli Lilly
|
CD3
|
Diabetes mellitus type 1
|
HUMANIZED
|
Phase III disappointed
|
| TGN1412 (CD28-superMAB)
|
TeGenero Immuno Therapeutics
|
CD28
|
B cell chronic lymphocytic leukemia (B-CLL) and rheumatoid arthritis,
|
HUMANIZED
|
Catastrophic systemic organ failure 2006 on phase I
|
| Tigatuzumab (CS-1008)
|
Daiichi Sankyo, Inc
|
TRAIL-R2 OrDR5
|
Several tumors (colorectal, pancreas, ovary)
|
HUMANIZED
|
phase II Clinical trials
|
| TNX-650
|
Tanox
|
IL-13
|
Refractory Hodgkin's lymphoma
|
HUMANIZED
|
Clinical trials
|
| Tocilizumab o atlizumab (Actemra®)
|
Hoffman-la Roche; Chugai Pharmaceuticals.
|
IL-6 receptor
|
Rheumatoid arthritis
|
HUMANIZED
|
EMEA 2009 FDA 2010
|
| Toralizumab (IDEC 131)
|
IDEC Pharmaceuticals Corporation
|
CD154 (CD40 ligand)
|
Immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis)
|
HUMANIZED
|
Trials halted on Phase II
|
| Tositumomab (Bexxar®)
|
Corixa Corp and GlaxoSmithKline
|
CD20
|
Non-Hodgkin follicular lymphoma
|
Mouse Ig-131I
|
FDA 2003
|
| Trastuzumab (Herceptin®)
|
Genentech Inc. (ROCHE)
|
ErbB2 (HER2/neu)
|
Breast cancer
|
HUMANIZED
|
FDA 1998 EMEA 2000
|
| Tremelimumab o Ticilimumab (CP-675,206)
|
Pfizer
|
CD 152 (CTLA-4)
|
Melanoma/small cell lung cancer/prostate cancer
|
HUMAN
|
Clinical trials
|
| Tucotuzumab celmoleukin
|
EMD pharmaceuticals
|
EpCAM
|
Several tumors
|
HUMANIZED- celmoleukin (IL-2)
|
Clinical trials
|
| Tuvirumab
|
PDL (Protein Design Labs) BioPharma
|
Hepatitis B virus
|
Chronic hepatitis B
|
HUMAN
|
Phase I clinical trials in 2001
|
| Urtoxazumab
|
TMA-15 TEIJIN
|
E coli Shiga like toxin II B (STEC 0-157 infection)
|
Diarrhoea by Escherichia coli (serotype 0121)
|
HUMANIZED
|
Phase II Clinical trials
|
| Ustekinumab (Stelara®)
|
J&J
|
P40fromIL-12 and IL-23
|
Psoriasis, multiple sclerosis
|
HUMAN
|
FDA 2009 EMEA 2008
|
| Vapaliximab
|
(HUVAP) Biotie Therapies (VAP-1 fully human) Turku-Finland
|
Vascular adhesion protein (VAP-1)
|
Inflammation
|
CHIMERIC (mouse/human)
|
Phase I (2002)
|
| Vedolizumab
|
Millennium Pharmaceuticals
|
Integrin α4β7
|
Ulcerative colitis and Crohn's disease
|
HUMANIZED
|
Clinical trials
|
| Veltuzumab
|
Immunomedics, Inc
|
CD20
|
Non-Hodking's lymphoma
|
HUMANIZED
|
Clinical trials
|
| Vepalimomab (vepalimomabum)
|
Biotie Therapies (VAP-1 fully human)
|
Vascular adhesion protein (VAP-1)
|
Inflammation
|
MOUSE HUMAN
|
Phase 2 enabling work underway.(Scifinder)Immunoglobulin M, anti-(human vascular adhesion protein VAP-1)(mouse monoclonal 1B2μchain) disulfide with mouse monoclonal 1B2 light chain, dimer
|
| Visilizumab (Nubion)
|
PDL BioPharma Inc
|
CD3
|
Multiple myeloma and diabetes mellitus type 1
|
HUMANIZED
|
Clinical trials
|
| Volociximab
|
PDL BioPharma and Biogen Idee
|
Integrin α5β1
|
Solid tumors
|
CHIMERIC(mouse/human)
|
Clinical trials
|
| 99mTc -Votumumab (HumaSPECT®)
|
KS Biomedix Ltd, Non commercialized
|
CTAA16.88 cytokeratin polypeptides
|
Detection of colorectal tumor. Diagnostic imaging
|
HUMAN- 99mTc
|
EC withdrawal
|
| Zalutumumab (HuMax-EGFR)
|
GenMab
|
EGFR
|
Squamous cell carcinoma resistant to chemotherapy
|
HUMAN- BSC
|
Clinical trials
|
| Zanolimumab (HuMax-CD4)
|
GenMab
|
CD4
|
Rheumatoid arthritis/psoriasis/melanoma/T cell lymphoma
|
HUMAN
|
Clinical trials
|
| Zolimomab aritox
|
XOMA Corp CD5 Plus; H65-RTA; Orthozyme CD5plus; XZ-CD5; XomaZyme-H65
|
CD5
|
Systemic lupus erythematosus / graft versus host disease
|
MOUSE-ricin protein
|
the studies failed to show positive effects(Immunotoxin)
|